Anavar Results In Bodybuilding: Comparing The Before And After
**What are anabolic‑androgenic steroids (AAS) and why are they prescribed?**
Anabolic‑androgenic steroids are synthetic derivatives of the male sex hormone testosterone. In a clinical setting they are used for:
| Indication | Why it’s used |
|------------|---------------|
| **Endocrine disorders** (e.g., delayed puberty, hypogonadism) | To replace missing testosterone and support normal
growth hormone stack or sexual development |
| **Muscle‑wasting diseases** (e.g., chronic kidney disease, AIDS‑related cachexia) | To stimulate protein synthesis, increase lean body mass, and improve strength |
| **Certain anemias** (rarely) | To enhance erythropoiesis indirectly by increasing testosterone levels |
| **Autoimmune myopathies** (in some protocols) | As part of immunosuppressive regimens |
### 2. How It Works
1. **Binding to Androgen Receptor**
Testosterone or its analogs enter target cells and bind the intracellular androgen receptor (AR). The hormone–receptor complex translocates to the nucleus.
2. **Gene Transcription Modulation**
In the nucleus, the AR complex attaches to specific DNA sequences called androgen response elements (AREs), recruiting co‑activators or co‑repressors that influence transcription of downstream genes.
3. **Protein Production**
The altered gene expression leads to synthesis of proteins involved in cell proliferation, differentiation, and metabolism. In muscle cells this results in increased protein synthesis; in bone tissue it enhances osteoblast activity.
4. **Feedback Regulation**
Elevated androgenic activity can suppress hypothalamic–pituitary production of gonadotropins (LH/FSH) via negative feedback, reducing endogenous testosterone secretion over time.
---
### Key Points
| Aspect | Effect |
|--------|--------|
| **Testosterone Levels** | Decrease due to suppression of LH → reduced endogenous synthesis. |
| **Gonadotropin Secretion** | Reduced LH (and FSH), causing testicular atrophy and decreased sperm production. |
| **Muscle Mass / Strength** | Initially may improve from anabolic effects; long‑term benefit depends on hormone balance. |
| **Sexual Function** | May decline because of lower endogenous testosterone, despite high exogenous levels. |
| **Bone Density & Mood** | Typically maintained or improved by androgen action. |
| **Side Effects** | Gynecomastia, fluid retention, increased PSA, potential for cardiovascular risk. |
---
## 4. Practical Clinical Implications
| Clinical Goal | How to Use Testosterone (androgens) | Typical Dosing Regimens |
|---------------|-------------------------------------|-------------------------|
| **Hypogonadism / Low T** | Replace physiologic testosterone; aim for serum total T 300‑800 ng/dL, free T 5–15 pg/mL. | 1–2 mg/kg/day intramuscular (IM) or subcutaneous injections of testosterone cypionate/ enanthate (e.g., 50–100 mg IM every 2–4 weeks). |
| **Anabolic/Catabolic Conditions** | High-dose testosterone to stimulate muscle protein synthesis; monitor for side effects. | 200–500 mg IM every 1–2 weeks, or continuous infusion (≈0.5 mg/kg/h) in ICU settings. |
| **Hypogonadism/Androgen Deficiency** | Low dose therapy to maintain libido and energy. | Oral 5‑α‑reductase inhibitors avoided; use testosterone gel or patch for steady release. |
### Side‑Effects of High‑Dose Testosterone
| Category | Common Effect | Management |
|----------|---------------|------------|
| **Hematologic** | Polycythemia (↑ hematocrit) | Monitor CBC, consider phlebotomy or aspirin. |
| **Cardiovascular** | Hypertension, tachycardia, arrhythmias | BP monitoring, antihypertensives if needed. |
| **Hormonal** | Suppression of LH/FSH → decreased fertility; gynecomastia | Consider aromatase inhibitors (anastrozole) or tamoxifen for breast pain. |
| **Metabolic** | Dyslipidemia (↑ LDL), insulin resistance | Diet, statins if indicated. |
| **Psychiatric** | Mood swings, aggression, insomnia | Monitor mood; adjust dose accordingly. |
---
## 5. Practical Implementation Plan
### A. Pre‑Treatment Baseline Assessment
1. **Medical History & Physical Examination**
- Cardiovascular risk factors, liver function, endocrine status.
2. **Laboratory Tests (baseline)**
- Testosterone (morning), LH/FSH, estradiol, prolactin, SHBG, PSA, CBC, CMP (liver enzymes).
3. **Imaging / Bone Density** if clinically indicated.
4. **Lifestyle Assessment** – diet, exercise, smoking/alcohol.
### B. Initiation of Therapy
- Start with **low dose oral testosterone**, e.g., 25 mg Tocris, twice daily (or per the product’s recommended dosing). Adjust based on tolerability and serum levels.
- Monitor for side effects: acne, hirsutism, mood changes.
### C. Follow‑Up Schedule
| Time | Assessment |
|------|------------|
| 2–4 weeks | Check serum testosterone; assess side effects; adjust dose. |
| 6–8 weeks | Repeat serum level; check CBC (to monitor for erythrocytosis), LFTs, lipid panel. |
| Every 3 months thereafter | Serum levels, CBC, LFTs, lipids; adjust dosing accordingly. |
### D. When to Switch or Discontinue
- **Serum testosterone remains <200 ng/dL** after adequate titration (e.g., >2–4 mg/day) → consider alternative agent or combination therapy.
- **Persistent side effects**: uncontrolled hypertension, severe hypertriglyceridemia, significant liver enzyme elevation → discontinue and reassess.
- **Erythrocytosis**: hematocrit ≥48% in men (or ≥47% in women) → reduce dose or switch to another agent.
---
## 4. Practical Recommendations for a Primary Care Physician
| Topic | Key Points |
|-------|------------|
| **Initial Screening** | - Check fasting glucose, HbA1c <7%.
- Lipid panel: aim LDL < 100 mg/dL (or <70 mg/dL if high‑risk).
- Liver enzymes: ALT/AST. |
| **Medication Choice** | - Start with **Metformin** (if no contraindications).
- If liver enzymes >3
